RxDoctor Payments Data

Haley Maxwell, PA

Physician Assistant · Parrish, FLNPI 1639769847

Payments from drug & device makers

$9,329in general payments, 2019–2025

Across 410 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Lilly USA, LLC$879
  • Pfizer$782
  • Amgen$503
  • Novo Nordisk$472
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$9,329100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,329 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$91,553
Medicare patients
372
Services billed
1,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$46,792
MounjaroTirzepatide23$34,225
EliquisApixaban15$20,148
EntrestoSacubitril/Valsartan13$12,864
Tresiba Flextouch U-100Insulin Degludec18$9,771
SynthroidLevothyroxine Sodium19$1,517
Telmisartan60$1,334
Omeprazole76$1,321
Atorvastatin Calcium144$1,118
Rosuvastatin Calcium145$1,101
Gabapentin48$968
Levothyroxine Sodium115$968
Pantoprazole Sodium58$672
Tamsulosin Hcl48$654
Estradiol16$653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$472$46,79237 claims
Lilly USA, LLCMounjaro$879$34,22523 claims
PfizerEliquis$782$20,14815 claims
NovartisEntresto$377$12,86413 claims
AbbVieSynthroid$1,598$1,51719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Parrish

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →